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The Warburg effect is a peculiar feature of cancer’s metabolism, which is an attractive 
therapeutic target that could aim tumor cells while sparing normal tissue. Matrine is an 
alkaloid extracted from the herb root of a traditional Chinese medicine, Sophora flavescens 
Ait. Matrine has been reported to have selective cytotoxicity toward cancer cells but with 
elusive mechanisms. Here, we reported that matrine was able to reverse the Warburg 
effect (inhibiting glucose uptake and lactate production) and suppress the growth of human 
colon cancer cells in vitro and in vivo. Mechanistically, we revealed that matrine significantly 
decreased the messenger RNA (mRNA) and protein expression of HIF-1α, a critical 
transcription factor in reprogramming cancer metabolism toward the Warburg effect. As a 
result, the expression levels of GLUT1, HK2, and LDHA, the downstream targets of HIF-1α 
in regulating glucose metabolism, were dramatically inhibited by matrine. Moreover, this 
inhibitory effect of matrine was significantly attenuated when HIF-1α was knocked down or 
exogenous overexpressed in colon cancer cells. Together, our results revealed that matrine 
inhibits colon cancer cell growth via suppression of HIF-1α expression and its downstream 
regulation of Warburg effect. Matrine could be further developed as an antitumor agent 
targeting the HIF-1α-mediated Warburg effect for colon cancer treatment.
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INTRODUCTION
Cancer cells have remarkably increased metabolic requirements in comparison to normal cells. In 
order to support this demand, cancer cells consume much more glucose and produce lactic acid 
rather than catabolizing glucose by the tricarboxylic acid cycle. By this way, they would be able to 
consume additional nutrients and divert those nutrients into macromolecular synthesis pathways 
to support their rapid proliferation (Vander Heiden et al., 2009). This phenomenon is termed as the 
“Warburg effect,” as first described by Otto Warburg in 1920s (Warburg, 1956).
Hypoxia-induced factor 1 (HIF-1) is a heterodimeric protein composed of two subunits, HIF-1α 
and HIF-1β. HIF-1α is accurately regulated by oxygen concentration while HIF-1β is constitutively 
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expressed in cells. Under normoxic conditions, HIF-1α is 
hydroxylated on proline residue 402 and/or 564, which is required 
for binding of the von Hippel–Lindau (VHL) protein, the 
recognition subunit of an E3 ubiquitin ligase that targets HIF-1α 
for proteasomal degradation. Upregulation of HIF-1α is usually 
detected in cancer cells, which is caused by the hypoxic condition 
in the solid tumor as well as the activation of some oncogene 
(Denko, 2008; Masoud and Li, 2015). As a critical mediator of the 
Warburg effect, HIF-1 stimulates the expression and activation 
of glycolytic enzymes, thereby supporting the Warburg effect in 
human cancers (Lu et al., 2002; Courtnay et al., 2015). Targeting 
HIF-1α to inhibit the Warburg effect has emerged as a promising 
anticancer therapeutic strategy (Semenza, 2003; Chen et al., 2007).
Colon cancer is one of the leading causes of cancer death in 
the developed world. Surgery is the main treatment for colon 
cancer, while radiotherapy and chemotherapy are also important 
to improve prognosis. However, chemotherapy resistance is still 
a big challenge for treatment. Discovery of novel drugs for colon 
cancer treatment would be the way to overcome this dilemma. 
Matrine is an active component extracted from the herb root of a 
traditional Chinese medicine, Sophora flavescens Ait. Matrine has 
long been used for the treatment of viral hepatitis, liver cirrhosis, 
and skin inflammatory (Liu et al., 2003). Recently, the antitumor 
effect of matrine has provoked considerable interest, manifested 
as inhibiting cell proliferation, accelerating apoptosis, inducing 
cell cycle arrest and differentiation, suppressing metastasis, 
invasion, and angiogenesis in a variety of malignant cells (Zhang 
et al., 2010; Guo et al., 2013; Liu et al., 2014; Ma et al., 2015; Xu 
et al., 2017), including colon cancer (Chang et al., 2013; Zhang et 
al., 2014; Gu et al., 2018). However, the precise molecular target 
of matrine is still mostly unknown. In this article, we found that 
matrine inhibited the transcription of HIF-1α, thereby reversing 
the Warburg effect (inhibiting glucose uptake and lactate 
production) and suppressing cell growth in human colon cancer 
cells in vitro and in vivo. These results provide a theoretical basis 
for the application of matrine as an effective anticancer drug for 
colon cancer.
MaTERIalS aND METHODS
antibodies and Reagents
Matrine was purchased from Sigma-Aldrich (Catalog No. 
M5319, purity above 97%, Saint Louis, MO, USA). Antibody 
for HIF-1α was purchased from BD Bioscience (Catalog No. 
610958, San Diego, CA, USA). 2-(N-(7-Nitrobenz-2-oxa-1,3-
diazol-4-yl)Amino)-2-deoxyglucose (2-NBDG) was purchased 
from Thermos Fisher Scientific (Eugene, OR, USA). All other 
reagents were from Sigma-Aldrich (Shanghai, China) unless 
stated otherwise.
Cell lines and Cell Culture
Human colon cancer cell lines HCT116 and SW620 were obtained 
from Cell Bank of Chinese Academy of Sciences (Shanghai, China). 
All the cell lines were authenticated by SNP and short tandem repeat 
analyses by the provider. HCT116 cells were cultured in McCoy’s 5A 
medium. SW620 cells were cultured in modified Eagle’s medium. 
All the medium was supplemented with 10% fetal bovine serum 
(HyClone, Logan, UT, USA), 100 μg/ml streptomycin, and 100 U/
ml penicillin (Life Technologies, Carlsbad, CA, USA).
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium Bromide assay
Cell viability was detected using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were 
seeded at 1 × 104 cells/well in 96-well plates and then treated 
with matrine as indicated. After treatment, 50 μl of 5 mg/ml 
MTT solution was added to each well and incubated at 37°C for 
4 h. The formazan crystals formed were then dissolved in 150 μl 
DMSO, and the absorbance of the solution was then obtained on 
a microplate reader at λ570 nm. Results were presented as the 
percentage loss of cell viability compared with control.
Colony-Forming assay
Cells were seeded in six-well plate. After 24 h, cells were treated 
with matrine for 12 h. After treatment, cells were washed with 
PBS, harvested by trypsinization, counted, and seeded into 
six-well dishes at 1,000 cells/well. The cells were incubated for 
another 10 days, then fixed and stained with 1% crystal violet in 
ethanol. Colonies containing 50 or more cells were scored. Colony 
formation was normalized to the colony forming efficiency of the 
non-drug-treated group to calculate the surviving fraction.
Tumor Xenograft in Nude Mice
The animal experiments were approved by the Committee on 
the Ethics of Animal Experiments of Xiamen University. Female 
Balb/c nude mice aged 4–6 weeks were inoculated with 2 × 106 
HCT116 cells by subcutaneous injection into the right flank. 
When tumors reached an average volume > 120 mm3, mice were 
administrated with 100 μl saline (control group) or 0.32 mmol/
kg matrine every day by intraperitoneal injection. The tumor 
volumes were determined according to the equation (volume = 
length×width2) and recorded every day.
Glucose Uptake assay
Glucose uptake of cells was measured by 2-NBDG uptake 
as described by Zou et al. (2005). Briefly, cells were seeded in 
12-well plates at a density of 70–80% and treated with matrine as 
indicated. After treatment, cells were harvested and resuspended 
in Krebs-Ringer’s HEPES Buffer (KRB) solution, and incubated 
with 100 nmol/L 2-NBDG at 37°C in 5% CO2 for 30 min. 
The 2-NBDG uptake reaction was stopped by removing the 
incubation medium and washing the cells twice with pre-cold 
phosphate buffered saline (PBS). One microgram per milliliter 
of propidium iodide (PI) solution was used to distinguish dead 
cells. The fluorescence was then measured by flow cytometry.
In Vivo Glucose Uptake assay
Nude mice bearing SW620 colon cancer cells xenografts were 
administrated with 3.7–7.4 MBq (100–200 μCi) of [18F]-FDG 
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via the tail vein. After injection, the mice were anesthetized with 
isoflurane (5% for induction and 2% for maintenance) to minimize 
mice movement and minimize muscle uptake of glucose. 40 min 
after injection, a whole body CT scan (6 min) were performed 
following with microPET images (5 min). The microPET and CT 
images were generated separately and then fused using Inveon 
Research Workplace version 4.1 (Siemens Medical Solutions, 
Inc., USA). The images were reconstructed using ordered subset 
expectation maximization with three-dimensional resolution 
recovery (OSEM 3D) with CT-based attenuation correction and 
scatter correction. For data analysis, the region of interests (ROI) 
were manually drawn and covered the whole tumor on the CT 
images. This ROI was copied to the corresponding PET images. 
The percentage injected dose per gram tissue (%ID/g) of the tumor 
in the ROIs were recorded as the uptake of glucose.
lactate Production assay
Cells were seeded in six-well plates at a density of 70–80% 
and treated with matrine as indicated. After treatment, the 
culture medium of each well was carefully collected. The lactate 
concentration in the medium was measured using the Lactate 
Colorimetric Assay Kit II from BioVision, Inc. (Milpitas, CA) 
according to manufacturer’s instruction. Briefly, samples were 
mixed with the provided reaction reagent and incubated for 
30 min in room temperature, and the optical density (OD) 
value was measured at 450 nm. The measured OD values of the 
samples were compared with that of the standard lactate control 
to calculate the concentration of lactate. The levels of lactate were 
then normalized to the non-drug-treated group.
Quantitative Real-Time Polymerase  
Chain Reaction
Cells were seeded in six-well plates at a density of 70–80% 
and treated with matrine as indicated. Total RNA was isolated 
using TRIzol reagent (Takara, Dalian, China). RNA was 
treated with DNase to remove genomic DNA and was reverse-
transcribed into cDNA using Primescript™ RT reagent kit 
(Takara, Dalian, China) according to the manufacturer’s 
protocol. Real-time quantitative polymerase chain reaction 
(PCR) was carried out with the SYBR Green I fluorescent dye 
method (SYBR® Premix Ex TaqTM II, Takara, Dalian, China) 
and the StepOnePlus real-time PCR apparatus (Applied 
Biosystems, Australia). The sequences of primers used are as 
follows: forward: 5′-TATTGCACTGCACAGGCCACATTC-3′ 
and reverse: 5′-TGATGGGTGAGGAATGGGTTCACA-3′ for 
HIF-1α; forward: 5′-GGCATTGATGACTCCAGTGTT-3′ and 
reverse: 5′-ATGGAGCCCA GCAGCAA-3′ for GLUT1; forward: 
5′-TCACGGAGCTCAACCATGAC-3′ and reverse: 5′-CTG 
CAGTAGGGTGAGTGGTG -3′ for HK2; forward: 5′-GCCCGA 
CGTGCATTCCCGATTCCTT-3′ and reverse: 5′-GAC GGCTT 
TCTCCCTCTTGCTGACG-3′ for LDHA; forward: 5′-CGT 
GTACTACAATGAGGCTGC-3′ and reverse: 5′-CTGGTCT 
GAAGATCTGGCCG-3′ for β-tubulin. The amplification 
specificity was checked by melting curve analysis. The relative 
expression of messenger (mRNA) was calculated using the 2−△△ Ct 
method through normalizing to mRNA of β-tubulin. The fold 
change of matrine treated group was calculated by normalizing 
to control (non-drug treated) group.
Western Blotting
Cells at 60–80% confluence were washed with PBS and lysed 
directly into SDS–PAGE loading buffer. Twenty micrograms of 
protein was analyzed by SDS–PAGE and transferred to PVDF 
membrane. Primary antibodies (HIF-1α BD Bioscience 610958, 
HIF-1β CST-3414) were used at 1:1,000 in 5% milk in Tris-
buffered saline with 0.05% Tween-20. Immunopositive bands 
were visualized by Amersham ECL™ Plus Western Blotting 
Detection Kit (GE Healthcare, Piscataway, NJ, USA).
Immunohistochemistry
Standardized immunohistochemical stainings were performed 
on formalin-fixed paraffin-embedded (FFPE) xenograft tumor 
tissue. Five-micrometer-thick sections were placed on coated 
glass slides, deparaffinized, and rehydrated and then subjected 
to high-pressure antigen retrieval in a pressure cooker for 3 
min in preheated 10 mmol/L sodium citrate buffer (pH 6.0). 
Endogenous peroxidase activity was blocked by incubation 
in 3% hydrogen peroxide for 10 min, and nonspecific staining 
was eliminated by incubating the sections with 10% normal 
goat serum for 15 min at room temperature. The sections were 
incubated with the primary antibody (HIF-1α BD Bioscience 
610958, GLUT1 Abcam ab115730, LDHA CST-3582, HK2 
Abcam ab209847) at 4°C overnight. Sections were incubated 
with diluted biotinylated secondary antibody for 10 min and then 
incubated with the avidin-biotin-peroxidase complex for another 
10 min with repeated washing steps. Staining was visualized 
using 3,3’-diaminobenzidine solution (Maxim, Fuzhou, China). 
Sections were then counterstained with hematoxylin after 
dehydration and scanned by Motic digital slide scanner.
Ribonucleic acid Interference and HIF-1α 
Overexpression
RNA interference of HIF-1α expression was performed by 
stable cell lines expressing short hairpin RNA (shRNA). 
GV112 lentiviruses vectors (GeneChem, Shanghai, China) 
were cloned with shRNA targeting HIF-1α (target sequence: 
GCTGGAGACACAATCATAT and CTCTTTGTGGTTGGAT 
CTA). Lentivirus was packaged and infected cells. Stable cell 
lines were selected by puromycin and the knockdown effect 
was confirmed by qPCR and Western blotting. Human HIF-1A 
cDNA was cloned into pCMV5 vectors and were transfected 
into HCT116 and SW620 cells by Lipofectamine 2000. Forty-
eight hours of after transfection, the overexpression effect was 
confirmed by qPCR and Western blotting, and cytotoxicity assay 
was performed as indicated.
Statistical analysis
The SigmaPlot version 11.0 software package was used for 
statistical analysis. The results are presented as mean ± standard 
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error (SEM). Data were analyzed by one-way analysis of variance 
(ANOVA) or Student’s t-test. P < 0.05 was considered significant.
RESUlTS
Matrine Inhibits Colon Cancer Cell Growth
To validate the anticancer effect of matrine on colon cancer 
cells, we first examine the impact of matrine on HCT116 cells 
growth in different concentrations and treating time. As shown 
in Figure 1A, treatment of 4.0 mM matrine has significant 
growth inhibitory effect on HCT116 cells (green line). When the 
concentrations increased to 6.0 mM or above (8.0 mM), matrine 
shows significant cytotoxicity (Figure 1A, purple and black lines). 
We then calculated the IC50 of matrine for 12-h treatment in two 
different colon cancer cell lines (HCT116 and SW620). The IC50 of 
matrine in HCT116 cells is 6.1 mM, while SW620 cells are slightly 
more sensitive with IC50 of 4.9 mM (Figure 1B). The growth 
inhibitory effects were also validated by colony forming assay. As 
shown in Figures 1C, D, the surviving fraction decreased with 
increasing concentrations of matrine. These results suggest that 
matrine has an efficient anticancer effect on colon cancer cells.
To further validate our finding of matrine in tumor growth 
inhibition in vivo, nude mice harboring colon cancer cells 
xenograft were used. Mice were inoculated with HCT116 cells, 
and treatments were given when tumors reached an average 
volume of 120 mm3. Mice were randomly divided into control 
group (saline injection) and matrine group (0.32 mmol/kg, i.p/
day). And the tumor volumes were recorded every day for 7 
days. Figures 1E, F show the effect of matrine on the growth of 
HCT116 tumors in nude mice. There was a significant difference 
in the average tumor volumes between the control and matrine 
groups after 7 days of treatment.
Matrine Suppresses the Warburg Effects 
in Colon Cancer Cells
Warburg effect is one of the ways that cancer cells could sustain 
its rapid growth by facilitating the uptake of nutrition for biomass 
(Vander Heiden et al., 2009). Warburg effect is manifested as the 
increased glucose uptake and enhanced the production of lactate 
for generating ATP (Chen et al., 2007). To investigate whether 
the growth inhibitory effect of matrine is related to this metabolic 
change, we first detected the glucose uptake in HCT116 and SW620 
cells after matrine treatment. Figure 2A showed that treatment with 
matrine reduced glucose uptake in these two cell lines. Forty-eight 
hours of treatments with 4.0 mM matrine reduced glucose uptake of 
HCT116 by 42% and SW620 by about 80%, respectively (Figure 2B). 
FIGURE 1 | Matrine inhibited the growth of colon cancer cells in vitro and in vivo. (a) 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to 
examine cell viability after matrine treatment. Cells were treated with different concentrations of matrine as indicated for 12~48 h. Data were expressed as mean ± 
SEM, n = 6. **, P < 0.01. (B) MTT assay to examine the IC50 of matrine on HCT116 and SW620 cells for 12 h of treatment. Data are expressed as mean ± SEM,  
n = 6. (C) Representative pictures of colony forming assay to show the growth inhibition effect of different concentrations of matrine on colon cancer cells.  
(D) Surviving fraction of colony forming assay. Data were expressed as mean ± SEM, n = 3. *, P < 0.05, **, P < 0.01. (E) Growth curve of colon cancer xenograft 
tumor with/without matrine treatment. Data were expressed as mean ± SEM, n = 5. *, P < 0.05. (F) Representative pictures of colon cancer xenograft tumors with/
without matrine treatment.
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We next examined these effects in vivo by [18F]-FDG following 
microPET imagine. Nude mice harboring SW620 cells xenograft 
were first scanned for the glucose uptake in tumor xenograft. Then 
mice were treated with matrine for 0.32 mmol/kg. Twenty-four 
hours later, mice were re-scanned to detect the effect of matrine 
on glucose uptake. As shown in Figures 2C, D, matrine treatment 
substantially decreased glucose uptake in tumors. In the most 
sensitive mice, matrine inhibited glucose uptake by almost 80%. 
These data indicated that matrine inhibits glucose consumption in 
colon cancer cells in vitro and in vivo.
We then examined the effect of matrine on aerobic glycolysis 
by detecting the lactate production in matrine-treated colon cancer 
cells. We observed that matrine inhibited lactate production in 
HCT116 and SW620 cells. Treatments with 4.0 mM matrine for 
24 h reduced lactate production of HCT116 by around 28% and 
SW620 by about 20%, respectively (Figure 2E). Taken together, our 
results suggested that matrine interrupted colon cancer metabolism, 
i.e., matrine inhibited the Warburg effects by suppressing glucose 
consumption and lactate production in colon cancer.
Matrine Inhibits the Transcription and 
Protein Expression of HIF-1α
We next investigated the potential mechanisms governing 
the glycolytic phenotype changing associated with matrine 
treatment. HIF-1 pathway is a vital regulator of the Warburg 
FIGURE 2 | Matrine inhibited glucose uptake of colon cancer cells in vitro and in vivo. (a) Representative pictures of flow cytometry for accessing glucose uptake 
in HCT116 and SW620 cells. (B) Quantified data of glucose uptake determined by flow cytometry in HCT116 and SW620 cells after matrine treatment. Data 
were expressed as mean ± SEM, n = 3. *, P < 0.05, **, P < 0.01. (C) Quantified data of glucose uptake determined by microPET/CT. *, P < 0.05, paired Wilcoxon 
test. (D) Representative microPET/CT images of nude mice bearing subcutaneous SW620 tumor, which were acquired at 40 min after i.v. injection of [18F]-FDG. 
(E) Lactate production of HCT116 and SW620 cells with the treatment of matrine. Data were expressed as mean ± SEM, n = 4~6. *, P < 0.05.
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effect and upregulated HIF-1α expression has often been seen in 
many cancer cells. In the two colon cancer cell lines we tested, 
we found a detectable HIF-1α protein expression in normoxic 
condition (Figure 3A, first lands), which suggested that there 
is residual HIF-1 activity in these colon cancer cells. Treatment 
with different concentrations of matrine largely reduced HIF-1α 
protein expression (Figure 3A, left panel) in normoxic condition.
Protein degradation is known to be a vital regulatory process 
for cellular HIF-1α. To investigate whether the effect of matrine 
on HIF-1α is related to protein degradation, we treated cells with 
desferrioxamine (DFX), an iron chelator, which is known to mimic 
hypoxia condition by blocking HIF-1α degradation (Jaakkola et al., 
2001). Matrine reduced the protein level of HIF-1α even when the 
degradation was blocked by DFX (Figure 3A right panel). These 
results suggest that the negative regulation of matrine on HIF-1α 
proteins may be independent of the protein degradation.
We then evaluated matrine’s effect on the mRNA levels of 
HIF-1α. As indicated in Figure 3B, with the treatment of matrine 
for 12 h, the mRNA level of HIF-1α decreased in a dose-dependent 
manner in both HCT116 and SW620 cells. Thus, our data indicated 
that matrine inhibits HIF-1α mRNA expression, thereby reducing 
the protein level of HIF-1α. We also examined the effect of matrine 
on HIF-1β, which is the other component of heterodimeric HIF-1. 
However, matrine did not affect the mRNA and protein expression 
levels of HIF-1β in the two colon cancer cells (Figure S1).
To validate the inhibitory effect of HIF-1α by matrine in vivo, 
the xenograft tumors were isolated and immunohistochemistry 
was performed to examine HIF-1α expression. As shown in 
FIGURE 3 | Matrine suppressed messenger RNA (mRNA) transcription and protein expression of HIF-1α. (a) Western blotting shows the protein expression of 
HIF-1α in HCT116 and SW620 cells with 12 h treatment of 0~8.0 mM matrine together with or without 100 μM desferrioxamine treatment. (B) HIF-1α mRNA level 
as quantified by quantitative real-time-PCR in HCT116 and SW620 cells with the treatment of 0~8.0 mM matrine for 12 h. Data were expressed as mean ± SEM, 
n = 6. **, P < 0.01. (C) Immunohistochemistry showing the expression of HIF-1α in mouse xenograft tumors.
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Figure 3C, treatment with matrine could reduce the protein 
expression of HIF-1α in tumor xenograft samples.
Matrine Inhibits Glucose Metabolism-Related 
Gene Transcription in Colon Cancer Cells
The role of HIF-1α in reprogramming cancer metabolism toward 
the Warburg effect depends on its transcription activity, i.e., the 
activation of HIF-1 pathway would enhance the transcription of 
glucose metabolism gene such as glucose transporter 1 (GLUT1), 
hexokinases2 (HK2), and lactate dehydrogenase A (LDHA) 
(Semenza, 2003). GLUT1 facilitates the transport of glucose 
across the plasma membranes. Hexokinase 2 phosphorylates 
glucose to produce glucose-6-phosphate (G6P), the first step 
in most glucose metabolism pathways. LDHA catalyzes the 
synthesis of (S)-lactate from pyruvate. To examine the effect of 
matrine on these downstream effects of HIF-1α, we detected the 
mRNA level of these glucose metabolism-related enzymes after 
matrine treatment. As shown in Figure 4, 12 h treatment with 
matrine dose-dependently reduced the transcription of GLUT1, 
HK2, and LDHA in both HCT116 and SW620 cells.
We then examine protein levels of these three genes in 
tumor xenograft sample by immunohistochemistry. As shown 
in Figure 4D, treatment with matrine could reduce the protein 
levels of GLUT1, HK2, and LDHA.
The Inhibitory Effect of Matrine on 
Warburg Effect and Cell Growth Is 
attenuated by HIF-1α Knockdown or 
Overexpression in Colon Cancer Cells
To investigate whether the effect of matrine on reversing Warburg 
effect and inhibiting colon cancer growth is due to the inhibition 
on HIF-1α, we used shRNA to knockdown endogenous HIF-1α 
expression in HCT116 and SW620 cells. Two different shRNA 
targeting HIF-1α were constructed, and stable HCT116 and 
SW620 cell lines expressing shRNA were established. Quantitative 
real-time PCR (qRT-PCR) and Western blotting conferred the 
knockdown effect of these shRNAs (Figures S2A, B). Glucose 
uptake and the production of lactate were analyzed in HIF-1α 
knockdown cells. As shown in Figures 5A, B, knockdown of 
HIF-1α could reduce glucose uptake and lactate production 
in both HCT116 and SW620 cells, which confirms the role of 
HIF-1α in mediating Warburg effect. However, matrine did not 
reduce either glucose uptake or lactate production in HIF-1α 
knockdown cells, indicating that matrine’s effect on reversing 
Warburg effect depends on HIF-1α activity. We then carried out 
MTT assay to examine matrine’s effect on cell growth in HIF-1α 
knockdown cells. Knockdown of HIF-1α decreased the growth 
rate of HCT116 and SW620 cells (Figure S2C), which confirm 
that HIF-1α could be a therapeutic target for decelerating colon 
cancer cell growth. Meanwhile, the growth inhibitory effect of 
matrine was largely attenuated in HIF-1α knockdown groups 
compared to the control group (Figure 5C), especially at high 
concentrations (6.0~8.0 mM). These results suggested that the 
anticancer effect of matrine is in part, although not entirely, 
mediated by the inhibition of HIF-1α.
Furthermore, we examined whether overexpression of 
exogenous HIF-1α could rescue these two cells from matrine’s 
effect. qPCR and Western blot confirmed the overexpression of 
HIF-1α by transfecting pCMV5-HIF1A vectors (Figures S2D, E). 
Exogenous HIF-1α did not alter the growth rate of HCT116 and 
SW620 cells (Figure S2F). Matrine did not reduce glucose uptake 
and lactate production in HIF-1α overexpressed cells, indicating 
that exogenous HIF-1α could overcome matrine’s effect on 
reversing Warburg effect. Moreover, MTT assay shows that 
overexpression of HIF-1α could overcome a part of the toxicity 
of matrine on colon cancer cells (Figure 5F). This compensated 
effect of exogenous HIF-1α further confirmed the dependence of 
matrine’s cytotoxicity on the inhibition of HIF-1α.
DISCUSSION
The Warburg effect is the most distinguishing characteristic of 
energy metabolism in cancer cells. Multiple genes are involved 
in this complex controlled process. Modulating one gene may 
not be sufficient to suppress tumors and might even result 
in drug resistance. As a critical transcription factor, HIF-1 
activated several glycolysis genes (e.g., GLUT1, GLUT4, HK1, 
HK2, LDHA), hence is an attractive target for modulating the 
Warburg effect. HIF-1 pathway is usually overactive in cancer 
cells, which is because of the hypoxic condition in the core of 
solid tumor as well as the activation of oncogene or loss of tumor 
suppressors. Besides glucose metabolism, the hyperactivation of 
HIF-1 pathway also triggers many other crucial cancer hallmarks 
such as angiogenesis, cell invasion, and metastasis, and has a vital 
role in tumor survival and progression (Semenza, 2002; Wilson 
and Hay, 2011). Therefore, HIF-1 has emerged as a promising 
anticancer therapeutic target (Li and Ye, 2010; Rey et al., 2017). 
In the present study, we identified matrine as a new HIF-1α 
inhibitor. Matrine inhibits the mRNA and protein expression 
of HIF-1α, thereby suppressing the transcription of GLUT1, 
HK2, and LDHA, the downstream targets of HIF-1, which are 
the key enzymes involved in the glycolytic energy metabolism of 
cancer cells. These effects lead to the suppression of the Warburg 
effect, i.e., decreasing glucose uptake and lactate production. 
Knockdown of HIF-1α or overexpression of HIF-1α could 
completely reverse matrine’s effect on glucose uptake and lactate 
production, indicating that the effect of matrine on Warburg 
effect depends on the inhibition of HIF-1α. It is worth to note 
that although Warburg effect provides a great advantage to the 
growth of cancer cells, ablation of Warburg effect can not entirely 
suppress tumor growth due to the metabolic plasticity of cancer 
cells (Marchiq et al., 2015; de Padua et al., 2017; Zdralevic et al., 
2018a; Zdralevic et al., 2018b). Our results show that knockdown 
of HIF-1α or overexpression of HIF-1α largely attenuated the 
effect of matrine on cell growth, but not entirely as for the effect 
on glycolysis. This suggested that besides inhibiting HIF-1α and 
Warburg effect, other mechanisms may be involved in the growth 
inhibitory effect of matrine.
The growth inhibitory effect of matrine has been reported in 
a variety of cancers, including bladder cancer (Yang et al., 2017), 
breast cancer (Koh et al., 2008), myeloma (Zhou et al., 2015), 
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FIGURE 4 | Matrine inhibited the transcription of glucose metabolism-related genes in colon cancer cells. (a–C) Quantitative real-time-PCR analysis of GLUT1, 
HK2, and LDHA in HCT116 and SW620 cells following treatment with 0~8.0 mM matrine for 12 h. Data were expressed as mean ± SEM, n = 4~6. *, P < 0.05.  
**, P < 0.01. (D) Immunohistochemistry showing the expression of GLUT1, HK2, and LDHA in mouse xenograft tumors.
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lung cancer and hepatoma (Zhang et al., 2009), and also 
other colon cancer cells (Chang et al., 2013; Zhang et al., 
2014). Consistent with these studies, our results show that 
matrine could suppress colon cancer cell growth. A possible 
mechanism that mediates matrine’s growth inhibitory effect is 
the suppression of the PI3K/AKT pathway (Li et al., 2012; Yang 
et al., 2017). PI3K/AKT pathway modulates mTOR and inhibit 
HIF-1α protein synthesis and thus reverse Warburg effect. Our 
data illustrate that matrine modulate the mRNA level of HIF-1α. 
Moreover, we also found that overexpressing exogenous HIF-1α 
could overcome a part of matrine’s cytotoxicity, which indicates 
that matrine may not affect exogenous HIF-1α. Therefore, our 
FIGURE 5 | The growth inhibitory effect of matrine is attenuated by knockdown or overexpression of HIF-1α. (a) Quantified data of glucose uptake determined 
by flow cytometry in HCT116 and SW620 cells after 4.0 mM matrine treatment for 48 h. Data were expressed as mean ± SEM, n = 3. *, P < 0.05, **, P < 0.01, 
ns: not significant. (B) Lactate production of HCT116 and SW620 cells with the 4.0 mM matrine treatment for 24 h. Data were expressed as mean ± SEM, n = 3. 
*, P < 0.05, ns: not significant. (C) Cell viability accessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after treatment with 0~8.0 
mM matrine for 12 h. Data were expressed as mean ± SEM, n = 3~5, *P < 0.05. (D) Quantified data of glucose uptake determined by flow cytometry in HCT116 
and SW620 cells after 4.0 mM matrine treatment for 48 h. Data were expressed as mean ± SEM, n = 3. *, P < 0.05, ns: not significant. (E) Lactate production of 
HCT116 and SW620 cells with the 4.0 mM matrine treatment for 24 h. Data were expressed as mean ± SEM, n = 3. *, P < 0.05, ns: not significant. (F) Cell viability 
accessed by MTT assay after treatment with 0~8.0 mM matrine for 12 h. Data were expressed as mean ± SEM, n = 3~5, *P < 0.05, **, P < 0.01.
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finding of matrine’s inhibitory effect on colon cancer cell growth 
may be independent of the PI3K/AKT/mTOR pathway. Matrine 
may suppress HIF-1α at transcription level. NF-κB is a critical 
transcriptional activator of HIF-1α (Rius et al., 2008), and the 
suppression effect of matrine on NF-κB pathway has also been 
reported (Niu et al., 2017). It is possible that the transcriptional 
inhibitory effect of matrine on HIF-1α is via the suppression of 
NF-κB pathway.
Besides growth inhibition, the cytotoxicity of matrine on 
cancer cells has also been reported. In our study, we found 
that a high concentration of matrine has significant toxicity 
on colon cancer cells (Figure 1A). Apoptosis is one of the 
most common death forms induced by matrine (Liu and Jiang, 
2006; Luo et al., 2007; Zhang et al., 2010; Tan et al., 2013; Li 
et al., 2015; Gu et al., 2018). However, the mechanisms on how 
the apoptosis is triggered remain unknown. Current studies 
about matrine’s pro-apoptosis effect limited to that matrine 
could increase the expression of caspase-3, caspase-9 and 
some pro-apoptosis gene such as Bcl-2 family (Luo et al., 2007; 
Dai et al., 2009; Liang et al., 2012; Tan et al., 2013), without 
identifying the upstream targets. It is reported that HIF-1α 
has an anti-apoptosis effect on cancer cells. Nishimoto et al. 
reported that the activation of HIF-1α led to the acquisition of 
anti-apoptosis in human colon cancer cells (Nishimoto et al., 
2014). Similar results were reported in A549 lung cancer cells, 
that HIF-1α protected A549 cells from drug-induced apoptosis 
(Schnitzer et al., 2006). Those anti-apoptosis effects were also 
reported in HUMEC cells (Yu et al., 2004), and HepG2 liver 
cancer cells (Piret et al., 2004). Our finding illustrated that 
matrine inhibited the transcription and protein expression of 
HIF-1α, which might also partially explain the pro-apoptosis 
effect of matrine.
Cellular regulation of HIF-1α is primarily at the level of 
protein degradation or protein translation. Therefore, most 
of the identified HIF-1α inhibitors target these pathways. 
Examples include Wortmannin and LY294002 as the PI3K/
AKT inhibitors (Jiang et al., 2001), rapamycin and its chemical 
derivatives, CCI-779 which are mTOR inhibitors (Majumder 
et al., 2004), and geldanamycin that reduces heat shock protein 
90 binding to HIF-1α to destabilize folding and increase 
proteasomal degradation (Mabjeesh et al., 2002). Other novel 
HIF-1 inhibitors that induce the degradation of HIF-1a protein 
have been identified, such as PX-478 and YC-1, but their precise 
mechanisms of action remain to be established (Koh et al., 2008; 
Tsui et al., 2012). However, it has also been suggested that, under 
hypoxic conditions, levels of HIF-1α mRNA may be a limiting 
factor affecting the rate of protein translation (Young et al., 
2008). Since hypoxia is a common phenomenon in the core of 
solid tumor, our finding that matrine inhibit the mRNA level of 
HIF-1α would be more targeting the limiting factor and may be 
more utilized in solid tumor treatment.
One of the challenges for anticancer drug development is 
the reduction of side effect. The in vivo usage of matrine for 
cancer treatment in mice have been reported in several studies. 
The dose ranges from 25 to 100 mg/kg (Zhou et al., 2014; Wu 
et al., 2017; Cho et al., 2018; Shen et al., 2018; Wu et al., 2018). 
In our study, we use 80 mg/kg (0.32 mmol/kg) and the 7-days 
daily intraperitoneal administration shows distinct anticancer 
effect without significant side effects. All the mice were well 
tolerated without any sign of sickness. However, 7 days is 
quite a short-term course. Long-term exposure to matrine and 
closely examinations such as pathological sections for organ 
toxicity are required for the future development of matrine 
for clinical usage.
The present study has identified a new mechanisms of 
matrine’s anticancer effect. Our data illustrated that matrine 
could inhibit the transcription of HIF-1α and thus suppressed 
the HIF-1α-mediated Warburg effect. This finding provides a 
strong rationale for future clinical trials for the new application 
of matrine for colorectal cancer.
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